Publications by authors named "Samuel Jacobs"

Claim this Profile
N
NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated.
Tanner J Freeman, Thomas J George, Samuel A Jacobs, Greg Yothers, Tatjana Kolevska

Cancer Chemother Pharmacol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2 breast cancer that limits trastuzumab deruxtecan efficacy.
Dong Hu, Xiaoshuang Lyu, Zheqi Li, Prasanna Ekambaram, Anushka Dongre, Samuel A Jacobs

Nat Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies.
Maggie Chon U Cheang, Mothaffar Rimawi, Stephen Johnston, Samuel A Jacobs, Judith Bliss

NPJ Breast Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Samuel A Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J Montero

Breast Cancer Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Samuel A Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J Montero

Breast Cancer Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal Adenocarcinoma.
William A Hall, Jiahe Li, Y Nancy You, Marc J Gollub, Joseph R Grajo, Samuel A Jacobs

J Clin Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NSABP FC-6: Surgical conversion rate in colorectal cancer patients with unresectable, KRAS wild-type liver metastases receiving mFOLFOX7 plus cetuximab.
Lawrence D Wagman, David A Geller, Samuel A Jacobs, Nicholas J Petrelli, Carmen J Allegra

J Surg Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mental Health Among Firefighters: Understanding the Mental Health Risks, Treatment Barriers, and Coping Strategies.
Doug DeMoulin, Samuel Jacobs, Yoon-Sung Nam, Alyson B Harding, Adam F Moskowitz

J Occup Environ Med· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Charles E Geyer, Hanna Bandos, Priya Rastogi, Samuel A Jacobs, André Robidoux

Breast Cancer Res Treat· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Charles E Geyer, Hanna Bandos, Priya Rastogi, Samuel A Jacobs, André Robidoux

Breast Cancer Res Treat· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive factors influenced physical distancing adherence during the COVID-19 pandemic in a population-specific way.
Gillian A M Tarr, Keeley J Morris, Alyson B Harding, Samuel Jacobs, M Kumi Smith

PLoS One· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER/HER2 Breast Cancer.
Mitch Dowsett, Lucy Kilburn, Mothaffar F Rimawi, C Kent Osborne, Katherine Pogue-Geile, Samuel A Jacobs

Clin Cancer Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daytime sleepiness among Midwestern firefighters.
Yihe Shi, Bridget Bender, Patricia McGovern, Eun Mi Jung, Douglas DeMoulin, Samuel Jacobs

Arch Environ Occup Health· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.
Osama E Rahma, Greg Yothers, Theodore S Hong, Marcia M Russell, Y Nancy You, Samuel A Jacobs

JAMA Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neratinib-Plus-Cetuximab in Quadruple-WT () Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study.
Samuel A Jacobs, James J Lee, Thomas J George, James L Wade, Philip J Stella

Clin Cancer Res· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.
Arvind Dasari, Van K Morris, Carmen J Allegra, Chloe Atreya, Al B Benson, Samuel A Jacobs

Nat Rev Clin Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic.
Mitch Dowsett, Matthew J Ellis, J Michael Dixon, Oleg Gluz, John Robertson, Samuel A Jacobs

NPJ Breast Cancer· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Samuel A Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde

Breast Cancer Res· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microscaled proteogenomic methods for precision oncology.
Shankha Satpathy, Eric J Jaehnig, Karsten Krug, Beom-Jun Kim, Alexander B Saltzman, Samuel Jacobs

Nat Commun· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2 breast cancer.
Samuel A Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde

Breast Cancer Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10.
Jame Abraham, Albert J Montero, Rachel C Jankowitz, Mohamad Adham Salkeni, Jan H Beumer, Samuel A Jacobs

J Clin Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer.
Thomas J George, Aaron J Franke, A Bapsi Chakravarthy, Prajnan Das, Arvind Dasari, Samuel A Jacobs

Cancer· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations.
Rekha Pal, Ning Wei, Nan Song, Shaoyu Wu, Rim S Kim, Samuel A Jacobs

PLoS One· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.
Stephen Johnston, Shannon Puhalla, Duncan Wheatley, Alistair Ring, Peter Barry, Samuel A Jacobs

J Clin Oncol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
Joanne L Blum, Patrick J Flynn, Greg Yothers, Lina Asmar, Charles E Geyer, Samuel A Jacobs

J Clin Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis